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S U R G I C A L T E C H N I Q U E
orneal collagen cross-linking (CXL) has emerged as an effective technique in halting the progression of keratoconus and pellucid marginal degeneration. 1, 2 Current long-term follow-up studies have shown that CXL may prevent topographic and refractive progression and, to some extent, improve visual acuity and astigmatism and induce corneal fl attening. 1, 3 Few studies have reported the combined effect of CXL with the insertion of intracorneal ring segments (ICRS) in patients with keratoconus. These studies have demonstrated an overall additive effect of CXL and ICRS on visual acuity and keratometry. [4] [5] [6] The potential association of photorefractive keratectomy (PRK) and CXL has also been described previously. [7] [8] [9] [10] [11] However, few studies have reported the combined effect of the three procedures (ICRS, CXL, and PRK). 6, 12 The purpose of our study was to evaluate the effi cacy and safety of ICRS implantation followed, after reaching refractive stability, by same-day topography-guided PRK and CXL for visual rehabilitation in patients with low to moderate keratoconus.
PATIENTS AND METHODS

PATIENT POPULATION
Patients with keratoconus were included in this prospective, interventional, nonrandomized, noncontrolled study. All patients underwent ICRS implantation followed by same-day topography-guided PRK and CXL after achieving refractive stability following ICRS implantation. Inclusion criteria were intolerance to contact lenses, low to moderate keratoconus, and observed progression over the previous 6 months. Grading of keratoconus was based on Amsler-Krumeich classifi cation. C ABSTRACT PURPOSE: To evaluate the safety and effi cacy of intrastromal corneal ring segments (ICRS) implantation followed by same-day topography-guided photorefractive keratectomy (PRK) and ultraviolet-A/ribofl avin collagen cross-linking (CXL) in patients with low to moderate keratoconus.
METHODS:
Patients with low to moderate keratoconus and contact lens intolerance were included in the study. All patients fi rst underwent femtosecond laser-enabled placement of ICRS (Keraring, Mediphacos) (fi rst step). Same-day topography-guided PRK and CXL (second step) were subsequently performed in all patients after the refraction was stable (average 6 months [range: 3 to 11 months]).
RESULTS:
Thirteen eyes from 13 patients were included in the study. Based on values before the fi rst step and 6 months after the second step, signifi cant improvements were noted in uncorrected distance visual acuity (0.7Ϯ0.32 logMAR vs 0.08Ϯ0.08 logMAR), corrected distance visual acuity (CDVA) (0. 
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Progression was defi ned as one or more of the following changes over a period of 6 months: an increase of у1.00 diopter (D) in maximum keratometry, an increase of у1.00 D in manifest cylinder, and an increase of у0.50 D in manifest refraction spherical equivalent (MRSE). All patients were seeking to correct their refractive error and were adequately informed about the aim and expected results of this type of refractive surgery. All patients signed a consent form. This study was approved by the local ethical committee.
SURGERIES
As a fi rst step, all patients underwent femtosecond laser-enabled (IntraLase FS; Abbott Medical Optics, Abbott Park, Illinois) placement of ICRS (Keraring; Mediphacos, Belo Horizonte, Brazil). Segments sizes were determined according to the nomogram provided by the manufacturer. Depth of the ring channels was set at 75% to 80% of the thinnest pachymetry reading. At the end of the surgery, antibiotic and corticosteroid eye drops were administered, a soft bandage contact lens (BCL) was placed, and the eye was examined at the slit-lamp. The BCL was removed after the epithelial defect at the site of incision had closed (3 to 5 days postoperative). Postoperative medication included antibiotic/corticosteroid (tobramycin/dexamethasone) drops four times daily until the BCL was removed.
After the refraction was stable, the patient was scheduled for the second step, which was a sequential topography-guided PRK/CXL treatment performed on the same day. The average time between the fi rst step (ICRS implantation) and the second step (topography-guided PRK/CXL) was 6.18Ϯ2.75 months (range: 3 to 11 months). Refractive stability was determined by stable residual refractive error and K-readings in two consecutive visits at least 1 month apart.
The Schwind Amaris laser platform (Schwind eyetech-solutions, Kleinostheim, Germany) was used to perform phototherapeutic keratectomy (PTK) to remove 50 μm of the central 6.5 mm of corneal epithelium, and subsequently to perform all topography-guided PRK procedures. Topography-guided PRK treatments with a 6-mm optical zone were performed to normalize the cornea by reducing irregular astigmatism while treating part of the refractive error. Based on previous studies, 8 a limited topography-guided PRK treatment (maximum 50 μm of stromal ablation) was chosen to minimize tissue ablation and reduce the risk of iatrogenic ectasia. Mitomycin C 0.02 mg/mL was then applied for 30 seconds for all topography-guided PRK procedures.
Immediately after topography-guided PRK, CXL was performed according to the methodology described by Wollensak et al. 13 Ribofl avin (0.1% in 20% dextran T500 solution) was administered topically every 2 minutes for 30 minutes. Ribofl avin absorption throughout the corneal stroma and anterior chamber was confi rmed by slit-lamp examination. Isotonic ribofl avin was used whenever the stromal bed thickness was Ͼ400 μm; otherwise, hypotonic ribofl avin (0.1% with no dextran) was used for 10 minutes to swell the cornea to reach at least 400 μm. The cornea was aligned and exposed to ultraviolet A 365 nm light for 30 minutes at an irradiance of 3.0 mW/cm 2 . During ultraviolet A exposure, ribofl avin administration was continued every 2 minutes.
At the end of the surgery, antibiotic and corticosteroid eye drops were administered, a BCL was placed, and the eye was examined at the slit-lamp. The BCL was removed after the epithelial defect at the incision site had closed (3 to 5 days postoperative). Postoperative medication included diclofenc sodium 0.1 drops for 2 days and antibiotic/corticosteroid (tobramycin/dexamethasone) drops four times daily until the BCL was removed.
OUTCOME MEASURES
Uncorrected distance visual acuity (UDVA [logMAR]); corrected distance visual acuity (CDVA [logMAR]); ICRS Implantation With PRK and CXL/Al-Tuwairqi & Sinjab MRSE; mean, steep, and fl at topographical keratometry (K) values; and corneal coma were recorded for each patient at baseline, last follow-up after ICRS placement but prior to topography-guided PRK/CXL, and 6 months after topography-guided PRK/CXL. Safety index was calculated by the ratio postoperative ICRS placement CDVA/baseline CDVA (in logMAR). Effi cacy index was calculated by the ratio postoperative ICRS placement UDVA/baseline CDVA (in logMAR).
STATISTICAL ANALYSIS
GraphPad Prism version 5.03 software (GraphPad, San Diego, California) was used to perform the statistical analysis. The results in outcome measures after ICRS and PRK/CXL were analyzed using the paired two-tailed design. The results were considered statistically signifi cant for PϽ.05. The correlation between UDVA and CDVA after PRK/CXL and the preoperative baseline demographics were studied using the Pearson correlation coeffi cient.
RESULTS
Thirteen eyes from 13 patients were included. Table  1 summarizes the preoperative conditions in the eyes analyzed. Table 2 summarizes the postoperative visual and refractive outcomes after ICRS and 6 months after PRK/CXL.
After ICRS, a signifi cant improvement was noted in UDVA, keratometry values, and all components of the refractive error. No signifi cant change was noted in CDVA and coma (PϾ.05).
Additional signifi cant changes were seen at 6 months after PRK/CXL in comparison with the results after ICRS. A signifi cant improvement was noted in the same parameters. No signifi cant change was noted in CDVA, topographic astigmatism, or coma (PϾ.05).
All outcome measures showed signifi cant changes (PϽ.05) when the fi nal results were compared with baseline data (Fig 1) . After PRK/CXL, UDVA was available in 11 of 13 eyes. Safety and effi cacy indexes for the 11 eyes were 0.154 and 0.62, respectively. As shown in Figure 2 , approximately 63% of eyes gained у2 lines in CDVA, whereas no change in CDVA was noted in approximately 27% of eyes. Figure 3 illustrates the effi cacy of the two-step procedure.
No signifi cant correlations were observed between the fi nal UDVA and CDVA and the baseline parameters (Tables A and B , available as supplemental material in the PDF version of this article). DISCUSSION Placement of ICRS followed by combined topography-guided PRK/CXL appears to be safe and an effective option in select patients with keratoconus. The aim of our topography-guided PRK treatment was to normalize the cornea by reducing irregular astigmatism while treating part of the refractive error. To remove the minimum possible tissue, we decreased the effective optical zone diameter to 6 mm in all cases (compared to our usual treatment diameter of at least 6.5 mm in routine PRK and LASIK). We also planned 70% to 100% treatment of cylinder and sphere so as not to exceed 50 μm in planned stromal removal. Based on previous studies, we chose the value of 50 μm as the maximum ablation depth effected. 8 The prior use of ICRS would induce corneal fl attening and reduce keratometric astigmatism, allowing a controlled topography-guided PRK treatment to be performed with minimal tissue ablation.
Wavefront-guided ablation patterns are often misleading in keratoconus and seldom are applicable due to the high amount of aberrations present. On the contrary, topography-guided treatments can improve the corneal aspheric profi le and are suitable for laser corrections on irregular and highly aberrated corneas. 8, 14 In their 2007 study, Kanellopoulos and Binder described CXL with sequential topography-guided PRK 7 ; PRK was performed 12 months after CXL. Combined simultaneous topography-guided PRK followed by CXL has been described by Kymionis et al 10 and Kanellopoulos. 8 Kanellopoulos and Binder 7 conducted a large study that found topography-guided PRK and CXL improved UDVA, CDVA, MRSE, and keratometry and were more effective when applied on the same day. 8 Effi cacy of sequential PRK/CXL on keratoconus and pellucid marginal degeneration was further confi rmed in other studies.
9,10,15 Kymionis et al 6 described ICRS implantation with subsequent PRK/ CXL treatment in a patient with pellucid marginal degeneration. They reported a signifi cant improvement in fi nal UDVA and CDVA. Safety index 6 months after the second step of 11 eyes that underwent intracorneal ring segment implantation followed by same-day topography-guided photorefractive keratectomy and corneal collagen cross-linking in low to moderate keratoconus. Figure 3 . Efficacy index 6 months after the second step of 11 eyes that underwent intracorneal ring segment implantation followed by same-day topography-guided photorefractive keratectomy and corneal collagen cross-linking in low to moderate keratoconus.
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Iovieno et al 12 conducted a two-step case series study including fi ve eyes with keratoconus that underwent ICRS implantation followed by same-day PRK and CXL. Their results were promising, particularly after PRK/CXL. They reported that after ICRS implantation a signifi cant improvement was noted only in CDVA, whereas signifi cant improvements in all preoperative parameters were noted after PRK/CXL.
We conducted a relatively larger two-step case series, and our results showed signifi cant improvements in all parameters after ICRS except for CDVA and coma, whereas all parameters signifi cantly improved after PRK/CXL.
Several points make the comparison between the study by Iovieno et al 12 and ours diffi cult. First, the number of cases is different. Second, the type of ICRS implanted in their study was Intacs (Addition Technology, Des Plaines, Illinois), whereas we used the Keraring. Third, their baseline values were markedly different from ours. However, both studies showed good results in patients with low to moderate keratoconus.
There are some limitations to our study. The sample size is small. The period between the two steps is relatively short-there should be at least 6 months between procedures. In addition, the follow-up period after PRK/ CXL is relatively short; patients should be observed for at least 12 months. Further studies with a larger number of eyes and longer period of follow-up are needed. 
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